Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
June 16, 2021
Quick NaviTM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnostic Kit for Influenza and COVID-19
- Simultaneous testing for both viruses using a single test sample -
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Denka Company, Limited (Denka) announce that on June 16, Denka received manufacturing and marketing approval in Japan for Quick Navi ™ -Flu + COVID-19 Ag. This antigen rapid diagnostic kit enables medical professionals to simultaneously diagnose influenza and Covid-19. It is the latest product in the QuickNaviTM series of in vitro diagnostics. The combo kit is to be manufactured in Japan by Denka and will be co-marketed in the country by Denka and Otsuka.
In the past, it was necessary to test separately for the Covid-19 and influenza, but with this combination kit, the burdens of sample-taking, the time required for sample assessment, and the wait-time for review by a medical professional can be reduced.
This combination diagnosis kit reduces from a total of 15 minutes to a total of 10 minutes the assessment time for the presence or absence of a specific Covid-19 antigen.